{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Twelve weeks after completing chemoradiotherapy, a formal evaluation for response will be made, to include a careful evaluation by the head and neck surgeon, medical and radiation oncologists, and, as appropriate, a radiologic and an endoscopic examination. Patients will be considered to have achieved either a clinical complete response (i.e. complete disappearance of all clinically and radiologically detectable tumor) or to have clinical persistent disease.","groups":[{"description":"Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.","id":"OG000","title":"Arm A"},{"description":"Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.","id":"OG001","title":"Arm B"}],"paramType":"NUMBER","populationDescription":"intention to treat (ITT)","reportingStatus":"POSTED","timeFrame":"at 12 weeks after completing chemoradiotherapy","title":"Number of Patients With a Clinical Response-complete Disappearance of Detectable Tumor","type":"SECONDARY","unitOfMeasure":"participants"}